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background:  The impact of the recent American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines 
on ST-Elevation Myocardial Infarction (STEMI) is important as STEMI remains one of the most morbid and costly manifestations of 
cardiovascular disease (CVD).
Methods:  We analyzed a prospective cohort of STEMI patients from the Minneapolis Heart Institute’s Level One regional STEMI system 
from January 1st 2011 to May 30th 2014 with electronic health record data on patient demographics, low density lipoprotein cholesterol 
(LDL-C) levels, CVD risk factors and medication use, as well as outpatient physician visits. We calculated pre-STEMI eligibility for statin 
therapy according to ACC/AHA guidelines and the prior adult treatment panel (ATP III) guidelines. Of the 1,252 consecutively enrolled 
patients, we analyzed the 1,008 patients who had a clear culprit lesion.
Results:  In our sample, (n=1,008, mean age 63.7 [13.3] years, 71.5% male), 703 (70%) did not have known CVD at the time of 
presentation. Of those individuals, 22% were on a statin (only 3% a high-intensity statin). Of the 78% not on a statin, only 35% had a LDL-C 
not at goal by ATP III guidelines (mean LDL-C 110 (34) mg/dl). Conversely, 73% had a 10-year CVD risk >7.5% and would be statin-eligible 
according to ACC/AHA guidelines. Less than half (41%) of patients without known CVD prior to STEMI had seen a primary care physician 
in the past 2 years and only 3% had seen a cardiologist. Of the 305 (30%) patients with known CVD prior to STEMI, the mean LDL-C was 
95 (50) mg/dl, 69% were on a statin (22% a high-intensity statin) but less than half had seen a primary care physician (47%) or cardiologist 
(42%) in the past 2 years.
conclusion:  In a large cohort of STEMI patients, application of ACC/AHA guidelines substantially increased pre-STEMI statin eligibility 
compared to ATP III guidelines. Additionally, less than half of individuals with and without known CVD had seen a primary care physician 
in the 2 years prior to their STEMI. An increase in utilization of preventive care as well as application of a risk-based approach to statin 
allocation could significantly reduce rates of STEMI.
